Andere talen Can-Fite BioPharma Ltd.

Aandelen

CANF

IL0010944739

Beurs gesloten - TEL AVIV STOCK EXCHANGE Andere beurzen 16:24:13 16-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,6 ^ILa	-3,70%		-3,70%	0,00%

12/05	Transcript : Can-Fite BioPharma Ltd. - Special Call
09/05	Can-Fite BioPharma Ltd. Kondigt aan dat de FDA IND-goedkeuring geeft voor Namodenoson voor de behandeling van MASH-patiënten in een Fase IIb-studie	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Can Fite BioPharma : Immediate Report	13/05
Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study	13/05
CAN-FITE, FDA GRANTS IND CLEARANCE FOR NAMODENOSON TO TREAT MASH PATIENTS IN A PHASE IIB STUDY	10/05
Can Fite BioPharma : FDA grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09/05
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09/05
Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study	09/05
Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	06/05
Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602	06/05
LONG-TERM COMPLETE RESPONSE TO CAN-FITE'S NAMODENOSON IN PATIENT WITH ADVANCED LIVER CANCER ARTICLE PUBLISHED IN A LEADING SCIENTIFIC JOURNAL	26/04
Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal	25/04
CAN-FITE, SCIENTIFIC ARTICLE PUBLISHED BY KOL PRESENTS NAMODENOSON AS A PROMISING DRUG CANDIDATE TO TREAT ADVANCED LIVER CANCER AND MASH	16/04
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	15/04
Can Fite BioPharma : Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH	15/04
Can Fite BioPharma : Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	03/04
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients	03/04
Can-Fite Biopharma Ltd. Announces Submission of an Investigational New Drug Application to the U.S. Food and Drug Administration for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis, Also Known as Non-Alcoholic Steatohepatitis, for the Company's Ongoing Phase IIb Clinical Study	03/04
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV	01/04
Can Fite BioPharma : 20F FOR 2023	28/03
Can-Fite Biopharma Ltd. Announces Clinical Update	28/03
Can-Fite Reports 2023 Financial Results and Clinical Update	28/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Can-Fite BioPharma Ltd.

Aandelen

CANF

IL0010944739

Andere talen

Filters